Sai Parenterals Q1FY27 Revenue at ₹182 Cr, Up 175% YoY; Acquires Stakes in Pharma Assets
Sai Parenterals reported Q1 FY27 consolidated revenue of ₹182.4 crore, up 175% YoY. PAT was ₹7.9 crore. The company will redeploy ₹101.85 crore of IPO proceeds to acquire majority stakes in Saicriti Pharma (60% for ₹83.83 Cr) and Prathyak Laboratories (60% for ₹18.02 Cr). Acquisition of Prathyak to complete by Sep 30, 2026.
The substantial YoY growth in financial results and the strategic acquisition of stakes in two pharmaceutical assets, funded by IPO proceeds, are material events that are likely to have a significant impact on the company's future performance and strategic direction.
The company reported significant year-on-year growth in revenue and profit, along with strategic acquisitions that are expected to enhance its capabilities and market presence. The management commentary also indicates positive outlook and progress towards guidance.
Sai Parenterals Limited announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. Consolidated revenue from operations for Q1 FY27 stood at ₹182.4 crore, a significant increase of 174.8% compared to ₹20.4 crore in Q1 FY26. Gross profit rose to ₹76.2 crore with a margin of 41.8%, an expansion of 370 basis points quarter-on-quarter. EBITDA was reported at ₹27.3 crore, with a margin of 14.9%, an improvement of 50 basis points over Q4 FY26. Profit After Tax (PAT) for the quarter was ₹7.9 crore, with a PAT margin of 4.3%.
On a standalone basis, revenue from operations surged by 174.9% year-on-year to ₹56.2 crore. Gross profit stood at ₹22.1 crore with a margin of 39.3%. EBITDA increased by 292.7% year-on-year to ₹16.8 crore, with an EBITDA margin of 29.8%. PAT grew by 975.1% year-on-year to ₹8.9 crore, with a PAT margin of 15.8%.
The company's Board of Directors has approved a proposed variation in the utilization of IPO proceeds. ₹83.83 crore earmarked for capacity expansion and ₹18.02 crore for a new R&D center will be redeployed towards acquiring majority stakes in two operating pharmaceutical assets. The company proposes to acquire a 60% equity stake in Saicriti Pharma Private Limited for ₹83.83 crore to construct a critical-care injectable facility at Gummadidala, adhering to EU-GMP and USFDA standards. The total project cost is estimated at ₹215 crore, with completion targeted for April 2027. Additionally, SP Analytics Private Limited, the company's R&D subsidiary, will acquire a 60% equity stake in Prathyak Laboratories Private Limited for ₹18.02 crore. This acquisition is expected to complete by September 30, 2026. The company also announced the completion of funding for its Australian facility and the approval for incorporating a subsidiary in the United States.
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.